SUMMARY
A reduction in functional residual capacity (FRC) and an increase in lung water are observed commonly after extracorporeal circulation [1, 2] . This may lead to an increase in pulmonary shunt fraction, resulting in impairment of arterial oxygenation. The administration of antihypertensive drugs such as sodium nitroprusside (SNP), nitroglycerin, calcium channel blockers and other vasodilating drugs administered to control arterial hypertension in the immediate postoperative period may further influence venous admixture (Qs/Qt) and arterial oxygenation [3] [4] [5] . This study was undertaken to determine the influence of urapidil (postsynaptic otj-adrenoceptor blocker with additional a 2 -adrenoceptor block, agonist of cerebral 5-HT la receptors in the brain [6] [7] [8] [9] ), ketanserin (selective 5-HT 2 receptor antagonist with additional a 1 -blocking effects [10] [11] [12] ) and SNP on venous admixture and arterial oxygenation following coronary artery bypass grafting (CABG).
PATIENTS AND METHODS
The study was approved by the Ethics Committee and informed consent was obtained from all patients. Following CABG, 30 patients requiring control of postoperative arterial hypertension were allocated randomly to treatment with urapidil, ketanserin or sodium nitroprusside.
Before surgery, all patients had received |3-blockers, calcium channel blockers and long acting nitrates. All patients were premedicated with lorazepam 1-2 mg 30 min before induction of anaesthesia with etomidate, sufentanil and pancuronium. Additional doses of midazolam, sufentanil and pancuronium were administered for maintenance of anaesthesia. Lidoflazine 1 mg kg" for myocardial protection before extracorporal circulation [13] . The lungs were ventilated with a mixture of air and oxygen (Fi Ot 0.5).
Arterial hypertension (systolic arterial pressure > 155 mm Hg, or 30 mm Hg greater than preoperative values (average of three measurements)) recorded immediately after admission to the intensive care unit (ICU) was the indication for admission to the study. Patients were excluded if surgical blood loss was > 100 ml h" 1 , left ventricular function was impaired (ejection fraction < 0.5, LVEDP > 12 mm Hg, ventricular dyskinesia present, cardiac index < 2.5 litre min" 1 m"
2 ) or revascularization was incomplete. Inotropic support comprised less than 5 |ig kg" 1 min" 1 of dopamine. Patients with pulmonary, renal or hepatic dysfunction were excluded.
Routine haemodynamic variables (ECG, systolic (SAP) and diastolic (DAP) arterial pressures, central venous pressure (CVP), systolic (PAS) and diastolic (PAD) pulmonary artery pressures) were monitored continuously. Pulmonary capillary wedge pressure (PCWP) was determined intermittently before administration of the test drug and 5, 60, 180, 420 and 720 min after the beginning of its administration. At each point, cardiac output (Q) was measured by the thermodilution technique using cold isotonic saline. For each determination of Q, three measurements were obtained and averaged.
After admission of the patient to the ICU, the lungs were ventilated mechanically: FI OJ 0.5, PEEP + 5cmHjO. FI OJ was maintained at this value for 30 min; subsequently, it was adjusted to ensure normoxia, but was always > 0.3. Duplicate samples of arterial and mixed venous blood were obtained simultaneously before administration of the drug and 5, 60, 180, 420 and 720 min after administration. Arterial and mixed venous bloodgas tensions were measured in duplicate (ABL 4 Acid Base Laboratory) by the same individual on each occasion and averaged. Samples differing by > 1.3 kPa (Pa 0 ) were discarded and new samples obtained. Qs/Qt was calculated from a standard formula [14] . Cardiac index (CI), systemic (SVRI) and pulmonary (PVRI) vascular resistance indexes and alveolar-arterial oxygen partial pressure difference (PA Ot -Pa^) were calculated using standard formulae [15] .
After operation all patients received, over 24 h, 800 ml m~2 of a solution of glucose and balanced electrolytes. Blood and plasma were given according to the measured blood loss of each patient. All patients were sedated with fentanyl (single bolus) 3 |ig kg" 1578.0 (89.02)* 240.4(24.13)+ urapidil (initial bolus of 25 mg, followed by an infusion of 30-90 mg h~l) or ketanserin (initial bolus of 10 mg over 60 s, second bolus of 10 mg if necessary and an infusion of 1-5 ug kg" 1 mkr 1 ). Data are presented as mean (SEM) . Statistical analyses were performed using the Friedmann and Wilcoxon test (including Bonferroni correction) for intragroup comparisons and the Kruskal-Wallis and Mann-Whitney rank sum tests for intergroup comparisons. Significant differences were accepted when P < 0.05.
RESULTS
Thirty patients were studied (10 in each group). Two patients had to be withdrawn from the ketanserin group (one patient after 1 h, the second after 2 h), because of persistent hypertension. Three patients were withdrawn from the SNP group (after 3 h) because of an increase in Qs/Qt to > 30 % and an intolerable decrease in Pa^t despite an increase in Fi 0) .
There were no statistically significant differences between the groups in age, sex, weight or volume of colloids and crystalloids administered (table I) .
The maximum decrease in / (table II) .
In all groups there were significant decreases in SAP: maximum change in the SNP group was 60.2 (5.66) mm Hg, in the urapidil group 66.9 (6.3) mm Hg and in the ketanserin group 61.0 (6.11) mm Hg. A significant increase in heart rate of 13.1 (1.93) beat min-1 was seen in the SNP group compared with control and the urapidil group. PAS, PAP and PCWP decreased during administration of all the drugs. Although CVP decreased in all groups, none of the changes was significant. Q increased significantly in the SNP and urapidil groups. SVRI and PVRI decreased significantly in all groups (table III) .
DISCUSSION
Early postoperative hypertension after CABG is common and has an incidence of 30-60% [11, 16, 17] . In this study, it was controlled adequately by urapidil and SNP. However, in the ketanserin group, two patients had to be withdrawn from the study as treatment failures.
A significant increase in heart rate was observed after administration of SNP. Tachycardia following CABG may lead to an increase in myocardial oxygen consumption and result in myocardial ischaemia. Urapidil and ketanserin in this setting may be superior, as no significant increases in heart rate were seen in either of these groups. Prevention of tachycardia by urapidil may be a result of central inhibition of sympathetic activity by stimulation of 5-HT ls receptors in the medulla oblongata [7] . Ketanserin is thought to inhibit the sympathetic outflow of catecholamines and to lead to an inhibition of central ct 1 -adrenergic receptors [12, 17] .
. . An increased Qs/Qt with subsequent deterioration in systemic oxygenation was seen, in common with previous studies [1, 2] . Hypoxic pulmonary vasoconstriction, described first in 1946 by von Euler and Liljestrand [18] , is an important mechanism by which blood flow is diverted away from atelectatic or hypoxic regions of the lung. Many vasodilating drugs, including SNP, inhibit hypoxic pulmonary vasoconstriction, increasing Qs/Qt and decreasing Pao [2-5, 17, 19] . However, after administration of ketanserin and urapidil no increase in Qs/Qt or decrease in Pa Oj was seen in the present study, suggesting that these drugs did not inhibit hypoxic pulmonary vasoconstriction. This has been shown for ketanserin in patients with ARDS. The authors concluded that ketanserin might be a less potent pulmonary vasodilator than SNP [20] .
Urapidil and ketanserin appear to have advantages compared with SNP in the treatment of hypertension following CABG with respect to oxygenation and heart rate. However, 20 % of the patients receiving ketanserin were withdrawn as treatment failures.
